(Date:11/23/2009)...tive new study, a University of Utah scientist arg...r cause of global warming cannot be stabilized un...ds the equivalent of one new nuclear power plant e...e any substantial near-term departure from recentl... rates," says the new paper by Tim Garrett, an ass...
(Date:11/23/2009)...FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDLI )t...09astheex-dividenddateforits$200millionspecialdivi...ansactioncompletedonNovember2,2009.Thedividendwill...therecorddate,December1,2009.NASDAQhassettheapprox...ommonstockforpurposesoftheex-dividenddateonNovembe...
(Date:11/23/2009)...gnC or p.(IDC)announcedtodaythatDr.BruceL.A.Carter...ssfultrackrec or dinbiotechnologyexecutivemanageme...tics,inSeattle,WAandChiefScientificOfficeratNovoN ...ww.newscom.com/cgi-bin/prnh/20091123/SF15228 ) ,...cercommented,"IamdelightedtowelcomeDr.BruceCartera...
(Date:11/23/2009)...--CornerstoneTherapeuticsInc.(Nasdaq: CRTX ),aspec...opingandcommercializingsignificantproductsprimaril...thatCraigA.Collard,PresidentandChiefExecutiveOffic...alPiperJaffrayHealthCareConferenceat3:30PMETonWedn...rkCity. ,, AliveaudioandarchivedwebcastofCorner...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2...Pharma, Inc. (Nasdaq:,GORX) announced today that i...ts of its third fiscal quarter ended December 31, ...ET) with CEO, Mihir Taneja and VP/CFO,Carol Dore-F...erence call,by utilizing the following URL, http:/...?key=PVYY97BW8 thus,avoiding operator assistance ...
... Schering-Plough,Corporation (NYSE: SGP ) today ...on (FDA) has accepted the Peg-IFN (peginterferon a... (sBLA) for review and has,granted Priority Review...h,Stage III melanoma. Schering-Plough submitted it... The Priority Review designation is intended to ex...
...help doctors and clinicians identify best t...ease, BIRMINGHAM, Ala., Jan. 31 Clinical trial r...ation point to the need for more,detailed choleste...nd other,lipids. That,s according to Atherotech, a...xpanded cholesterol test called the VAP (Vertical ...
Other Biology Technology:GeoPharma Announces Third Quarter Conference Call 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Goat Anti-Human Rabenosyn 5 Polyclonal Antibody, Unconjugated from Abcam
Anti-Acetyl CoA Carboxylase Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119] NON-neutralizing Polyclonal Antibody, Unconjugated from Cell Sciences
Anti-AANAT Antibody, Unconjugated from CHEMICON
Biology Products: